Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03499873 · ClinicalTrials.gov registry record · Phase 3
Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 448
- Enrollment target
NCT03499873 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 448 participants.
The verdict
NCT03499873, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 448 participants
- Enrollment target
Study Summary
A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence study to evaluate the clinical equivalence and safety of Nepafenac 0.3% ophthalmic suspension (manufactured by Indoco remedies Ltd. for Actavis LLC) with IlevroTM (Nepafenac ophthalmic suspension), 0.3% of Alcon Laboratories, Inc. for the treatment of pain and inflammation associated with cataract surgery.
Interventions
- DRUG Placebos
- DRUG Nepafenac 0.3% Oph Susp
- DRUG Nepafenac 0.3% Oph Susp (reference)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 448 participants |
| Start Date | 2018-03-28 |
| Est. Completion | 2018-12-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03499873
The ClinicalTrials.gov registry entry for NCT03499873 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 448 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebos is the first listed.
NCT03499873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03499873 about?
NCT03499873 is a clinical study titled "Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension". A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence study to evaluate the clinical equivalence and safety of Nepafenac 0.3% ophthalmic suspension (manufactured by Indoco remedies Ltd. for Actavis LLC) with IlevroTM (Nepafenac ophthalmic suspension), 0.3% of A...
What is the current status of trial NCT03499873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 448 participants. The study started on 2018-03-28. Estimated completion is 2018-12-18.
What interventions are being tested in trial NCT03499873?
The interventions under investigation include: Placebos (DRUG), Nepafenac 0.3% Oph Susp (DRUG), Nepafenac 0.3% Oph Susp (reference) (DRUG).
Who is sponsoring clinical trial NCT03499873?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.